Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue- type plasminogen activator alone in acute ischemic stroke: propen- sity score-matched post hoc analysis. Stroke. 2015;46:461 464. doi: 174. Adeoye O, Sucharew H, Khoury J, Vagal A, Schmit PA, Ewing I, Levine SR, Demel S, Eckerle B, Katz B, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen ac- tivator in acute ischemic stroke: Full Dose Regimen Stroke Trial. Stroke. 175. Zinkstok SM, Roos YB; ARTIS Investigators. Early administra- tion of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380:731 737. doi: 176. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, Li Q, Billot L, Delcourt C, Bath PM, et al; ENCHANTED Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. 177. Jeong HG, Kim BJ,Yang MH, Han MK, Bae HJ, Lee SH. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. 178. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombec- tomy for ischemic stroke. N Engl J Med. 2018;378:1573 1582. doi: 179. Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Alteplase versus tenecteplase open-label, blinded endpoint study. Lancet Neurol. 2015;14:368 376. 180. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O Brien B, Bladin C, McElduff P, Allen C, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 181. 